Kerr Douglas Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
6
Insider Sells Sum
$2.94M

Insider Activity of Kerr Douglas

According to the SEC Form 4 filings, Kerr Douglas, being in a position of

  1. Chief Medical Officer at Dyne Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 5791 share for $117,569,
    over all time since 2025-03-05, has bought 0 shares, and sold 12901 share for $210,214.

Biography of Kerr Douglas

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $000
Sells
 $117,5695100

Comparison of Insiders on Amount of Buys and Sells

2026-08-13SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
1,556
0.001%
$26.28$40,892-34.09%
2026-06-16SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
887
0.0005%
$18.33$16,259+17.65%
2026-05-13SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
1,564
0.0009%
$18.36$28,715+1.3%
2026-03-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
904
0.0005%
$14.90$13,470+21.15%
2025-12-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
880
0.0006%
$20.72$18,234-10.11%
2025-09-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
873
0.0006%
$13.41$11,707+29.82%
2025-09-04SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
3,552
0.0025%
$13.27$47,135+39.35%
2025-06-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
1,342
0.0011%
$13.35$17,916+22.37%
2025-03-05SaleDyne Therapeutics, Inc.
DYN
Chief Medical Officer
1,343
0.0011%
$11.83$15,888+8.7%
Total: 9
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.